Insights

Market Need Rising Leptospirosis prevention demand is growing across Europe, creating opportunities for vaccines and workforce health programs. Target buyers include health authorities and employers in high risk sectors such as agriculture, water management, and veterinary services. A partnership strategy could emphasize integrated prevention programs, vaccination campaigns, and risk education through IMAXIO's leptospirose prevention platform.

Public Sector Partners There is a strong possibility to engage public health authorities and occupational safety agencies to fund and deploy prevention initiatives, potentially through government grants or public private partnerships. This could open opportunities for program management, training, and messaging campaigns delivered with IMAXIO expertise.

Employer Health Solutions With a small, nimble team, IMAXIO can offer turnkey B2B solutions for workplaces in high risk sectors, including vaccination, employee risk assessments, and training. Leverage the existing prevention platform to onboard employers and scale services efficiently.

Digital Outreach IMAXIO already maintains a digital footprint and compliance tools, presenting a chance to upsell digital health education, vaccination reminders, and program analytics to clients. The leptospirose prevention site can support lead generation and partner onboarding for enterprise customers.

Strategic Partnerships Current funding and vaccinology focus signal potential for strategic collaborations with larger pharma, CROs, or distributors seeking to expand zoonosis prevention portfolios. Exploring licensing, co development, or distribution agreements could accelerate market entry in Europe.

Imaxio Tech Stack

Imaxio uses 8 technology products and services including Snowplow, Weebly, Cloudflare, and more. Explore Imaxio's tech stack below.

  • Snowplow
    Analytics
  • Weebly
    Content Management System
  • Cloudflare
    Content Management System
  • Google Fonts API
    Font Scripts
  • iubenda
    Governance, Risk And Compliance
  • jQuery
    Javascript Libraries
  • Video.js
    Javascript Libraries
  • reCAPTCHA
    Security

Media & News

Imaxio's Email Address Formats

Imaxio uses at least 2 format(s):
Imaxio Email FormatsExamplePercentage
FLast@imaxio.comJDoe@imaxio.com
100%

Frequently Asked Questions

Where is Imaxio's headquarters located?

Minus sign iconPlus sign icon
Imaxio's main headquarters is located at 99 Rue de Gerland Lyon, Auvergne-rhône-alpes 69007 France. The company has employees across 1 continents, including Europe.

What is Imaxio's official website and social media links?

Minus sign iconPlus sign icon
Imaxio's official website is imaxio.fr and has social profiles on LinkedInCrunchbase.

What is Imaxio's SIC code NAICS code?

Minus sign iconPlus sign icon
Imaxio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Imaxio have currently?

Minus sign iconPlus sign icon
As of June 2026, Imaxio has approximately 23 employees across 1 continents, including Europe. Key team members include Coo - Directeur Des Opérations: S. L.Chairman Of The Board-Board: C. P.Qp / Pharmaceutical Affairs Director: V. H.. Explore Imaxio's employee directory with LeadIQ.

What industry does Imaxio belong to?

Minus sign iconPlus sign icon
Imaxio operates in the Biotechnology Research industry.

What technology does Imaxio use?

Minus sign iconPlus sign icon
Imaxio's tech stack includes SnowplowWeeblyCloudflareGoogle Fonts APIiubendajQueryVideo.jsreCAPTCHA.

What is Imaxio's email format?

Minus sign iconPlus sign icon
Imaxio's email format typically follows the pattern of FLast@imaxio.com. Find more Imaxio email formats with LeadIQ.

How much funding has Imaxio raised to date?

Minus sign iconPlus sign icon
As of June 2026, Imaxio has raised $3.8M in funding. The last funding round occurred on Apr 17, 2012 for $3.8M.

When was Imaxio founded?

Minus sign iconPlus sign icon
Imaxio was founded in 2000.
Imaxio logo

Imaxio

Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees

Imaxio is a small biotechnology company based in Lyon, in the Auvergne-Rhône-Alpes region of France. The firm specializes in vaccinology and the prevention of human leptospirosis, a zoonotic disease associated with occupational exposure. It collaborates with health authorities and professionals to reduce occupational risks and raises awareness about the disease in professional settings, supported by its dedicated prevention site leptospirose-prevention.fr. In France, leptospirosis incidence has risen since 2014, exceeding 600 cases per year, with about half of cases among working adults linked to occupational origins.

The company operates within the biotechnology research sector, focusing on preventive health and vaccines against leptospirosis. Its client base is primarily health authorities and professionals responsible for occupational health, with its Lyon base anchoring its regional presence.

Section iconCompany Overview

Headquarters
99 Rue de Gerland Lyon, Auvergne-rhône-alpes 69007 France
Website
imaxio.fr
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2000
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $3.8M

    Imaxio has raised a total of $3.8M of funding over 1 rounds. Their latest funding round was raised on Apr 17, 2012 in the amount of $3.8M.

  • $1M

    Imaxio's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $3.8M

    Imaxio has raised a total of $3.8M of funding over 1 rounds. Their latest funding round was raised on Apr 17, 2012 in the amount of $3.8M.

  • $1M

    Imaxio's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.